Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tamrintamab pamozirine + budigalimab
- Development stage
- Discontinued
- Lead developer
- AbbVie
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Tamrintamab pamozirine (SC-003) is a pyrrolobenzodiazepine-based antibody-drug conjugate (ADC) that targets dipeptidase 3 (DPEP3), a membrane-bound dipeptidase associated with tumor-initiating cells in ovarian cancer. It consists of a humanized IgG1 monoclonal antibody conjugated to a cytotoxic pyrrolobenzodiazepine dimer warhead via a plasma-stable linker. Budigalimab (ABBV-181) is a humanized recombinant monoclonal antibody targeting programmed cell death protein 1 (PD-1), an immune checkpoint receptor on T-cells, thereby inhibiting PD-1-mediated immunosuppression and enhancing anti-tumor immune responses. The combination was investigated in phase 1 clinical trials for platinum-resistant/refractory ovarian cancer[1][2][6][8].
- Other names
- tamrintamab pamozirine + budigalimab
02
Targets
DPEP3 (Dipeptidase 3)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on tamrintamab pamozirine + budigalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tamrintamab pamozirine + budigalimab.